Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Semler Scientific Inc's Business Segments
Semler Scientific Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2025
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 7
Regions Reported
-
Revenue Share by Reportable Segment - Q3 FY2025
- Single reportable segment100%
Revenue by Reportable Segment - Q3 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 7 | 100% |
Revenue by Product & Service Category - Q3 FY2025
- Variable Fee Licenses15.1%
- Hardware and Equipment Accessories1.3%
Revenue by Product & Service Category - Q3 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Variable Fee Licenses | $ 1 | 15.1% |
| Hardware and Equipment Accessories | $ 0 | 1.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Semler Scientific Inc
Semler Scientific Inc. is a medical technology company based in San Jose, California. It is focused on developing and marketing products and services that assist healthcare providers in measuring and analyzing peripheral arterial disease (PAD) and arterial stiffness. The company's main product is the FDA-cleared and CE Marked QuantaFlo™ System, which is used for early detection of PAD.
The QuantaFlo™ System is a non-invasive vascular testing device that utilizes a digital sensor and software to measure blood flow in the arteries. This test is commonly known as a Peripheral Arterial Disease (PAD) test or ankle-brachial index (ABI) test, which measures the blood pressure in the arms and legs to assess any blockages or narrowing of the arteries.
Semler Scientific Inc. also provides comprehensive software solutions that help healthcare providers manage the patient data collected from QuantaFlo™ tests. This software includes data analytics tools, reporting capabilities, and electronic medical record integration, making it easier for doctors to interpret and document test results.
The company aims to improve the accessibility and accuracy of PAD testing by offering an easy-to-use, cost-effective, and non-invasive solution. By detecting PAD early, Semler Scientific Inc. hopes to assist healthcare providers in identifying patients at high risk for cardiovascular disease and taking appropriate preventive measures.
Semler Scientific Inc. was founded in 2007 by Dr. Douglas Murphy-Chutorian, a physician and entrepreneur. The company went public in 2014 and is listed on the NASDAQ stock exchange under the ticker symbol SMLR. Since its inception, the company has experienced steady growth and has expanded its customer base both domestically and internationally.
The QuantaFlo™ System has received positive feedback from the medical community for its accuracy, simplicity, and efficiency. It has been adopted by a wide range of healthcare providers, including hospitals, clinics, and primary care physicians. The product has also garnered recognition and awards for its technological innovation and potential impact on patient outcomes.
In addition to its flagship product, Semler Scientific Inc. continues to invest in research and development to expand its portfolio of medical technology solutions. The company's goal is to provide healthcare providers with cutting-edge tools and technologies that enable early detection and intervention for various cardiovascular diseases.
Overall, Semler Scientific Inc. is a medical technology company that specializes in developing innovative and non-invasive solutions for the early detection and management of peripheral arterial disease. With its QuantaFlo™ System and comprehensive software solutions, the company aims to improve patient outcomes and empower healthcare providers to make informed decisions about cardiovascular health.
The QuantaFlo™ System is a non-invasive vascular testing device that utilizes a digital sensor and software to measure blood flow in the arteries. This test is commonly known as a Peripheral Arterial Disease (PAD) test or ankle-brachial index (ABI) test, which measures the blood pressure in the arms and legs to assess any blockages or narrowing of the arteries.
Semler Scientific Inc. also provides comprehensive software solutions that help healthcare providers manage the patient data collected from QuantaFlo™ tests. This software includes data analytics tools, reporting capabilities, and electronic medical record integration, making it easier for doctors to interpret and document test results.
The company aims to improve the accessibility and accuracy of PAD testing by offering an easy-to-use, cost-effective, and non-invasive solution. By detecting PAD early, Semler Scientific Inc. hopes to assist healthcare providers in identifying patients at high risk for cardiovascular disease and taking appropriate preventive measures.
Semler Scientific Inc. was founded in 2007 by Dr. Douglas Murphy-Chutorian, a physician and entrepreneur. The company went public in 2014 and is listed on the NASDAQ stock exchange under the ticker symbol SMLR. Since its inception, the company has experienced steady growth and has expanded its customer base both domestically and internationally.
The QuantaFlo™ System has received positive feedback from the medical community for its accuracy, simplicity, and efficiency. It has been adopted by a wide range of healthcare providers, including hospitals, clinics, and primary care physicians. The product has also garnered recognition and awards for its technological innovation and potential impact on patient outcomes.
In addition to its flagship product, Semler Scientific Inc. continues to invest in research and development to expand its portfolio of medical technology solutions. The company's goal is to provide healthcare providers with cutting-edge tools and technologies that enable early detection and intervention for various cardiovascular diseases.
Overall, Semler Scientific Inc. is a medical technology company that specializes in developing innovative and non-invasive solutions for the early detection and management of peripheral arterial disease. With its QuantaFlo™ System and comprehensive software solutions, the company aims to improve patient outcomes and empower healthcare providers to make informed decisions about cardiovascular health.
Semler Scientific, Inc. is a company that specializes in developing innovative medical technologies and diagnostic instruments, particularly focused on the management of chronic diseases such as diabetes and cardiovascular conditions. Here is an extensive breakdown of the segments, products, and services offered by the company:
Segments
1. Medical Diagnostics:
- Semlers primary focus is on diagnostic tools that aid in the assessment and management of chronic diseases. This segment is crucial for both initial evaluations and ongoing monitoring of patients.
2. Data Analytics and Software Solutions:
- The company also provides software that supports healthcare providers in analyzing patient data to inform treatment decisions and management plans.
3. Healthcare Services:
- In addition to diagnostic products, Semler may offer services that involve direct patient management through partnerships with healthcare providers and organizations, emphasizing quality care and outcomes.
Products
1. Diagnostic Instruments:
- DIASTAT®: A key product in Semlers portfolio, DIASTAT is designed for the easy, accurate assessment of various health parameters. This device is particularly known for its role in assessing cardiovascular health and glucose levels in diabetic patients.
- The design focuses on user-friendliness, making it suitable for use in both clinical settings and at home.
2. Peripheral Artery Disease (PAD) Testing:
- Semler provides devices that assist in diagnosing PAD, a condition where narrowed arteries reduce blood flow to the limbs, formulated with the intent to improve early detection and monitoring.
3. Chronic Disease Management Tools:
- This includes products tailored for ongoing monitoring and management of conditions such as diabetes. These tools often integrate advanced analytics to streamline patient care and therapeutic interventions.
Services
1. Training and Support:
- Semler offers comprehensive training for healthcare providers on how to effectively use their diagnostic devices and interpret the data generated through these tools. Support includes both technical assistance and clinical education.
2. Telehealth Services:
- In response to the growing need for remote healthcare solutions, Semler may provide telehealth services that enable healthcare providers to monitor patients remotely, leveraging their diagnostic products.
3. Clinical Research and Development:
- Semler may engage in clinical research initiatives aimed at refining and expanding its product offerings, ensuring that they stay at the forefront of innovation in medical diagnostics.
4. Custom Solutions:
- The company could also provide tailored solutions for healthcare organizations looking to integrate Semler technology into their existing workflows or require specialized services that meet their unique needs.
5. Patient Education and Outreach:
- Educating patients about their health conditions and the importance of monitoring is also a key service area. Through various programs and materials, Semler fosters awareness and engagement among patients.
Innovation Focus
Semler Scientific emphasizes the importance of continuous innovation within its product line and services. The company invests in research and development to enhance the efficacy and reliability of its diagnostic tools, striving to maintain high standards in the healthcare industry.
In summary, Semler Scientific, Inc. operates primarily in the medical diagnostics segment with a focus on chronic disease management. Their product range is designed to facilitate early detection and monitoring of health conditions, while the accompanying services aim to support both healthcare providers and patients in navigating chronic health challenges effectively.
Segments
1. Medical Diagnostics:
- Semlers primary focus is on diagnostic tools that aid in the assessment and management of chronic diseases. This segment is crucial for both initial evaluations and ongoing monitoring of patients.
2. Data Analytics and Software Solutions:
- The company also provides software that supports healthcare providers in analyzing patient data to inform treatment decisions and management plans.
3. Healthcare Services:
- In addition to diagnostic products, Semler may offer services that involve direct patient management through partnerships with healthcare providers and organizations, emphasizing quality care and outcomes.
Products
1. Diagnostic Instruments:
- DIASTAT®: A key product in Semlers portfolio, DIASTAT is designed for the easy, accurate assessment of various health parameters. This device is particularly known for its role in assessing cardiovascular health and glucose levels in diabetic patients.
- The design focuses on user-friendliness, making it suitable for use in both clinical settings and at home.
2. Peripheral Artery Disease (PAD) Testing:
- Semler provides devices that assist in diagnosing PAD, a condition where narrowed arteries reduce blood flow to the limbs, formulated with the intent to improve early detection and monitoring.
3. Chronic Disease Management Tools:
- This includes products tailored for ongoing monitoring and management of conditions such as diabetes. These tools often integrate advanced analytics to streamline patient care and therapeutic interventions.
Services
1. Training and Support:
- Semler offers comprehensive training for healthcare providers on how to effectively use their diagnostic devices and interpret the data generated through these tools. Support includes both technical assistance and clinical education.
2. Telehealth Services:
- In response to the growing need for remote healthcare solutions, Semler may provide telehealth services that enable healthcare providers to monitor patients remotely, leveraging their diagnostic products.
3. Clinical Research and Development:
- Semler may engage in clinical research initiatives aimed at refining and expanding its product offerings, ensuring that they stay at the forefront of innovation in medical diagnostics.
4. Custom Solutions:
- The company could also provide tailored solutions for healthcare organizations looking to integrate Semler technology into their existing workflows or require specialized services that meet their unique needs.
5. Patient Education and Outreach:
- Educating patients about their health conditions and the importance of monitoring is also a key service area. Through various programs and materials, Semler fosters awareness and engagement among patients.
Innovation Focus
Semler Scientific emphasizes the importance of continuous innovation within its product line and services. The company invests in research and development to enhance the efficacy and reliability of its diagnostic tools, striving to maintain high standards in the healthcare industry.
In summary, Semler Scientific, Inc. operates primarily in the medical diagnostics segment with a focus on chronic disease management. Their product range is designed to facilitate early detection and monitoring of health conditions, while the accompanying services aim to support both healthcare providers and patients in navigating chronic health challenges effectively.